Verified chronic severe giant cell myocarditis: an inevitable choice for heart transplantation

Myocarditis has polymorphic clinical manifestations and is one of the main causes of heart transplantation. We present a clinical case of a 43-year-old female patient who was admitted to the clinic with biventricular heart  failure (NYHA class 3–4). She periodically noted exacerbations of bronchitis against the background of prolonged smoking. Twenty-one months prior to hospitalization, she first noted a shortness of breath without an obvious connection with the infection. Her ejection fraction (EF) decreased to 34%, pleural and pericardial effusion was revealed. Coronary angiography found no abnormalities. However, MRI showed subendocardial contrasting of the  left ventricular (LV) apex. The diagnosis was myocarditis. Within six months, the patient received therapy with 30 mg/day prednisolone and cardiotropic therapy. Her shortness of breath intensified, and the lower extremities swelled. Examination in the clinic showed a sharp decrease in QRS voltage, QS complexes in the V1–V6 leads, dilation of all heart chambers, thrombus in the LV apical aneurysm, 16% EF, 3.9 cm VTI, 454 mmHg dp/dt, and a sharp increase in anticardiac antibody titers (up to 1:320). Endomyocardial biopsy was not performed due to the patient’s rapidly deteriorating condition, the need for cardiotonics, and signs of multiple organ failure. She was transferred to Shumakov National Medical Research Center of Transplantology and Artificial Organs, where extracorporeal membrane oxygenation was performed; orthotopic heart transplant was successfully performed. The patient’s condition was stable for the next year. Investigation of the explanted heart revealed a picture of giant cell myocarditis. Issues of diagnosis, possibility of a long-term chronic course, as well as methods of treatment of this variant of myocarditis, including the key role of heart transplantation, are discussed.

giant cell myocarditis, heart failure, left ventricular aneurysm, anticardiac antibodies, heart transplantation

1. Gautier SV, Poptsov VN, Koloskova NN, Zakharevich VM, Shevchenko AО, Muminov II et al. Heart transplantation waiting list of V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs. Trends from 2010 to 2017. Russian Journal of Transplantology and Artificial Organs. 2018; 20 (4): 8–13. [In Russ.,English abstract]. doi.org/10.15825/1995-1191-2018-4-8-13.

2. Caforio AL, Pankuweit S, Arbustini E et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34 (33): 2636–2648, 2648a–2648d. doi: 10.1093/eurheartj/eht210.

3. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC et al. American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation. 2016; 134 (23): e579–e646. PMID: 27832612, doi: 10.1161/CIR.0000000000000455.

4. Blagova OV, Osipova YV, Nedostup AV, Kogan EA, Sulimov VA. Clinical, laboratory and instrumental criteria for myocarditis, established in comparison with myocardial biopsy: A non-invasive diagnostic algorithm. Ter Arkh. 2017; 89 (9): 30–40. [In Russ., English abstract]. doi: 10.17116/terarkh201789930-40.

5. Ammirati E, Camici PG. Still poor prognosis for patients with giant cell myocarditis in the era of temporary mechanical circulatory supports. Int J Cardiol. 2018; 253: 122–123. doi: 10.1016/j.ijcard.2017.10.124.

6. Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss HP, Cooper LT. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015 Jun 15; 115 (12): 1733–1738. doi: 10.1016/j.amjcard.2015.03.023.

7. Elamm CA, Al-Kindi SG, Bianco CM, Dhakal BP, Oliveira GH. Heart Transplantation in Giant Cell Myocarditis: Analysis of the United Network for Organ Sharing Registry. J Card Fail. 2017; 23 (7): 566–569. doi: 10.1016/j.cardfail.2017.04.015.

8. Blagova OV, Nedostup AV. Сontemporary masks of the myocarditis (from clinical signs to diagnosis). Russian Journal of Cardiology. 2014; (5): 13–22. [In Russ., English abstract]. doi.org/10.15829/1560-4071-2014-5-13-22.

9. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis – natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997; 336 (26): 1860–1866. doi: 10.1056/NEJM199706263362603.

10. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M. Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail. 2016, 18: 1452–1458. doi: 10.1002/ejhf.606.

11. Ammirati E, Roghi A, Oliva F, Turazza FM, Frigerio M, Pedrotti P. Ventricular aneurysm as a complication of giant cell myocarditis. [Article in Italian]. G Ital Cardiol (Rome). 2015; 16 (6): 389–390. doi: 10.1714/1934.21040.

12. Blagova OV, Nedostup AV, Kogan EA, Sedov VP, Donnikov AE, Kadochnikova VV et al. DCMP as a clinical syndrome: results of nosological diagnostics with myocardial biopsy and differentiated treatment in virus-positive and virus-negative patients. Russian Journal of Cardiology. 2016; 21 (1): 7–19. [In Russ., English abstract]. doi.org/10.15829/1560-4071-2016-1-7-19.

13. Gautier SV, Shevchenko AO, Kormer AYa, Poptsov VN, Saitgareev RSh, Shumakov DV, Zakharevich VM. Three decades of heart transplantation in the Shumakov center: long-term outcomes. Vestnik transplantologii i iskusstvennyh organov. 2015; XVII (2): 70–73. doi.org/10.15825/1995-1191-2018-4-8-13.

14. Gkouziouta A, Miliopoulos D, Karavolias G, Lazaros G, Kaklamanis L, Kelepeshis G et al. Acute cytomegalovirus infection triggering fatal giant cell myocarditis. Int J Cardiol. 2016; 214: 204–206. doi: 10.1016/j.ijcard.2016.03.202.

15. Zhou Z, Chen X, Liu G, Pu J, Wu J. Presence of Multiple Autoimmune Antibodies Involved in Concurrent Myositis and Myocarditis and Myasthenia Gravis Without Thymoma: A Case Report. Front Neurol. 2019; 10: 770. doi: 10.3389/fneur.2019.00770.

16. Suarez-Barrientos A, Wong J, Bell A, Lyster H, Karagiannis G, Banner NR. Usefulness of Rabbit Anti-thymocyte Globulin in Patients With Giant Cell Myocarditis. Am J Cardiol. 2015; 116 (3): 447–451. doi: 10.1016/j.amjcard.2015.04.040.

17. Patel AD, Lowes B, Chamsi-Pasha MA, Radio SJ, Hyden M, Zolty R. Sirolimus for Recurrent Giant Cell Myocarditis After Heart Transplantation: A Unique Therapeutic Strategy. Am J Ther. 2019; 26 (5): 600–603. doi: 10.1097/MJT.0000000000000796.

18. Shevchenko AO, Nikitina EA, Koloskova NN, Shevchenko OP, Gautier SV. Controlled arterial hypertension and adverse event free survival rate in heart recipients. Cardiovascular therapy and prevention. 2018; 17 (4): 4–11. doi: 10.15829/1728-8800-2018-4-4-11.

19. Montero S, Aissaoui N, Tadié JM, Bizouarn P, Scherrer V, Persichini R et al. Fulminant giant-cell myocarditis on mechanical circulatory support: Management and outcomes of a French multicentre cohort. Int J Cardiol. 2018; 253: 105–112. doi: 10.1016/j.ijcard.2017.10.053.

20. Fallon JM, Parker AM, Dunn SP, Kennedy JLW. A giant mystery in giant cell myocarditis: navigating diagnosis, immunosuppression, and mechanical circulatory support. ESC Heart Fail. 2020; 7 (1): 315–319. doi: 10.1002/ehf2.12564.

21. Elamm CA, Al-Kindi SG, Bianco CM, Dhakal BP, Oliveira GH. Heart Transplantation in Giant Cell Myocarditis: Analysis of the United Network for Organ Sharing Registry. J Card Fail. 2017; 23 (7): 566–569. doi: 10.1016/j.cardfail.2017.04.015.